Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. - Test2 - elhamkhani - TriplyDB

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.

http://www.wikidata.org/entity/Q37074093

about

Low dose rapamycin exacerbates autoimmune experimental uveitis The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.Pharmacogenomics of adverse drug reactions: practical applications and perspectives.Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium Pharmacogenetics may Influence Tacrolimus Daily Dose, but not Urinary Tubular Damage Markers in the Long-Term Period after Renal Transplantation.Pharmacogenetics of immunosuppressants: progress, pitfalls and promises.Pharmacogenetics of Crohn's disease.The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.Statin regulation of CYP3A4 and CYP3A5 expression.Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.Deciphering calcineurin inhibitor nephrotoxicity: a pharmacological approach.Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs.The genetics of kidney transplantation.Hsp90 inhibition: elimination of shock and stress.The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient.The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model.Effect of bifendate on the pharmacokinetics of talinolol in healthy subjects.CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: short-term and long-term efficacy and safety results.Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers.SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand.

P2860

Q28730115-B7D21029-E9D8-4877-92F3-0BD52FA084D0 Q33521351-79603B79-8382-44B1-87F7-421B115692AE Q34987138-50E382E0-B530-467B-ABC8-D58186E720EA Q36630081-378660F8-2A6C-4D72-B0AA-BED5C311782D Q37041351-02834A02-E4DB-400F-9FE0-44FE181460E2 Q37176567-6EAFE410-9CBB-4EF3-B713-85AADE76B92C Q37205946-511C78E4-F6FC-45E6-B063-D39EFE601F96 Q37513374-7B31031C-1E5F-40B0-B6FC-090B0C3567BC Q37521064-9128402E-8591-457F-A5B7-09200BCFB3B6 Q37657540-9BAA2615-5DE2-47BD-8246-1DEAFD0CE0AE Q37806767-7F3B0444-AD0D-4933-9801-BD6891BFF779 Q37892531-0DB81CBE-0F93-47A0-8C4C-5FE43FCCF735 Q37933139-3EA4A09D-5165-489E-AA9C-382000AB6607 Q38291354-DA5B1764-D13C-4B1D-ABEA-365A9663B771 Q38585232-482FFEA6-406B-42AF-B7C6-68A076251BDF Q38976077-CA553A18-E224-4CD9-A9E7-4A5A98798D24 Q43257603-BFB14476-45EE-4963-A5D4-BC7BC26AE0A8 Q44805468-1E94FB93-986B-440F-92F3-C499F1AF7C92 Q46173047-C465C4B1-2EA1-49E9-8744-713AA6B1E532 Q48203172-6B0C3027-279A-4170-9A22-B51E57B051DF Q48238550-E52BBAA9-4877-4264-9D28-5CB6330B6E37 Q48349326-4231A4CA-4E2C-45FE-8061-F86124E808B3 Q51297212-0B31F39F-F2DA-4D53-8680-8AD380651863 Q53384595-D3C1DB7C-EFAF-4250-9F30-920DF0C2EF34 Q55497899-69B97427-4291-46F6-A57D-A1F99D324530

P2860

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.

http://www.wikidata.org/entity/Q37074093

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.

@en

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.

@nl

type

label

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.

@en

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.

@nl

prefLabel

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.

@en

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.

@nl

P1433

Q37074093-52836835-F2C4-4731-92CF-78A9D3426B6F

P1476

Q37074093-0872871B-215D-4BD2-9FEC-E661398A002E

P2093

Q37074093-4B5AFE58-84A0-47DE-97DC-187CF8ABD148

Q37074093-9B56F48C-9316-45A7-9488-D000C814DD38

Q37074093-A7EAE7D4-417A-4C36-8DFC-052A7D1CD2F8

Q37074093-D08ADECE-BE6E-47A6-94A7-9913183376B2

P2860

Q37074093-0182FC39-383B-40B2-AE83-CFFE5EA76608

Q37074093-02FAFF45-99FA-4F50-AE09-829E9D4BC3C1

Q37074093-0C8811C9-0CA7-4A36-9339-A4E2D0E0B320

Q37074093-0D0452C7-5760-4A7E-B01E-0B19D74984AD

Q37074093-118BFD46-E06B-43BF-A782-E325F160E2EE

Q37074093-167BF3E4-678D-49A3-AC2A-835E83896DFB

Q37074093-1802CFC8-2954-4FFF-AEDE-04B99BFCB131

Q37074093-193C0411-AD5C-40ED-A073-536A00341304

Q37074093-1D8C5A3F-A3A3-4312-A7F4-7546A515E258

Q37074093-26C56E9D-369F-40FD-9800-4284260A4E41

P304

Q37074093-0DD1536C-9DD0-4F70-BE92-C366691BC95B

P31

Q37074093-46B72BE5-349C-413A-8B3A-CDB153DB4151

P356

Q37074093-B5D1C1FB-D048-4D31-9303-5DED810F0ACA

P433

Q37074093-53CD9A52-5E00-43E4-BB0D-E49460743EC4

P478

Q37074093-24F04794-DCCA-4FF0-AC7A-9156D006F9DA

P577

Q37074093-554D92DB-1FDD-4023-B4BA-D4AF20C24355

P698

Q37074093-1001FD39-59BB-4F42-A486-B43E091E31B1

P356

14622416.8.7.835

P1433

Pharmacogenomics

P1476

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.

@en

P2093

Christophe Legendre

http://www.w3.org/2001/XMLSchema#string

Dany Anglicheau

http://www.w3.org/2001/XMLSchema#string

Eric Thervet

http://www.w3.org/2001/XMLSchema#string

Philippe Beaune

http://www.w3.org/2001/XMLSchema#string

P2860

The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons

Chronic renal failure after transplantation of a nonrenal organ

Clinical importance of the cytochromes P450

Genetic contribution to variable human CYP3A-mediated metabolism

Genetic variability in CYP3A5 and its possible consequences.

Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance.

The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups.

Summary of information on human CYP enzymes: human P450 metabolism data.

Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity.

Pharmacogenomics--drug disposition, drug targets, and side effects.

P304

835-849

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14622416.8.7.835

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18240909

http://www.w3.org/2001/XMLSchema#string